fampridine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
fampridine: clinical details
Prescribing considerations
- Initiation and supervision should be by a physician experienced in managing MS.
- Document walking ability before treatment and reassess objective and patient-reported benefit after initiation; discontinue if meaningful benefit is not demonstrated.
- Use caution with mild renal impairment, factors lowering seizure threshold, previous allergic reactions, infection susceptibility, and cardiac rhythm or conduction symptoms.
- Dizziness and balance disorder may increase fall risk.
Contraindications and cautions
- Hypersensitivity to fampridine or an excipient.
- Current or previous seizure.
- Moderate or severe renal impairment, defined as creatinine clearance below 50 mL/min.
- Concurrent fampridine-containing products.
- Concurrent OCT2 inhibitors such as cimetidine.
Monitoring
- Estimate renal function before treatment and regularly thereafter, particularly in older adults.
- Monitor walking response and continued clinical benefit.
- Stop permanently if a seizure or serious hypersensitivity reaction occurs.
- Review new neurological symptoms, falls, palpitations and interacting medicines.
Clinical pharmacology
Fampridine blocks potassium channels, reducing ionic-current leakage and prolonging repolarisation in demyelinated axons. It has a narrow therapeutic index, crosses the blood–brain barrier and is eliminated mainly unchanged through the kidneys, including active OCT2-mediated secretion.
Formulation and product differences
- The selected product is a film-coated prolonged-release tablet for oral use.
- Modified-release characteristics are lost if the tablet is split, crushed, dissolved, sucked or chewed.
- Bottle and blister presentations are authorised; bottles contain a desiccant and should be used within the stated period after opening.
fampridine preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 10 mg
fampridine interactions
A complete medicines review is important, particularly for products affecting fampridine’s kidney clearance.
Other medicines containing fampridine or 4-aminopyridine
Concurrent use is contraindicated because exposure and serious adverse-effect risk may increase.
Cimetidine
This OCT2 inhibitor reduces renal secretion of fampridine and must not be used concurrently.
Metformin, carvedilol or propranolol
These OCT2 substrates require caution because they may affect fampridine’s renal transport.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.